Global IDO inhibitor

IDO inhibitor Comprehensive Study by Type (BMS-986205, Dcellvax, Epacadostat, F-001287, Galanal, Others), Application (Aolpecia, Cervical Cancer, Gastric Cancer, Glioma, Others) Players and Region - Global Market Outlook to 2030

IDO inhibitor Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 20.3%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
The growing prevalence of cancer will help to boost the global IDO inhibitor market in the forecasted period. IDO inhibitor is an orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential immunomodulating and antineoplastic activities. IDO inhibitors can break the tumor's immune escape mechanisms by inhibiting the TRP depletion either by inhibiting the IDO enzyme in cancer cells as well as in surrounding mesenchymal stroma cells (MSC) and thus reducing the TRP conversion or by acting as TRP. the growing research and development regarding cancer will help to trigger the global IDO inhibitor market. According to AMA Research, the market for IDO inhibitor is expected to register a CAGR of 20.3% during the forecast period to 2030. This growth is primarily driven by Rising Prevalence of Cervical Cancer .

AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Volume UnitN
Value UnitUSD (Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


The Commodity Chemicals sector in the North America region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Vendors, such as Bristol-Myers Squibb Company(United States), Pfizer Inc (United States), Ensemble Therapeutics Corp (United States), F. Hoffmann-La Roche Ltd (Switzerland), Genentech Inc (United States), Globavir Biosciences Inc (United States), Incyte Corp (United States), IO Biotech ApS (Denmark), Kyowa Hakko Kirin (Japan) and Netherlands Translational Research Center BV (Netherlands), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
In October 2022 Pfizer Inc. announced today the completion of its acquisition of Biohaven Pharmaceutical Holding Company Ltd., the maker of NURTEC® ODT (rimegepant), an innovative migraine therapy approved for both acute treatment and prevention of episodic migraine in adult
In November , 2018 Kyowa Hakko Kirin Co., Ltd. announces that the company has entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc., to initiate a Phase 1 clinical study of Kyowa Hakko Kirin's novel IDO inhibitor, KHK2455, in combination with avelumab*, a human anti-PD-L1 antibody for solid tumors.Leading key players are focusing on strategic partnerships to improve their products and services. Companies are focusing on increasing their client base to strengthen market position and to enhance product & service offerings.

Influencing Trend:
Increasing Investment in Research & Development Globally and Growing Gastric Cancer Worldwide

Market Growth Drivers:
Rising Prevalence of Cervical Cancer and Growing Demand from Emerging Countries

Challenges:
Increase in Purchasing Power of Developing Countries

Restraints:
Stringent Rules and Regulations of the Government

Opportunities:
The Growing Healthcare Expenditure in Developed and Developing Countries

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mainly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Vendors landscape impacting the market's growth. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Data Sources of IDO inhibitor Market Study

Primary Collection: InMail, LinkedIn Groups, Survey Monkey, Google, and Other professional Forums are some of the mediums utilized to gather primary data through key industry participants and appointees, subject-matter experts, C-level executives of IDO inhibitor Industry, among others including independent industry consultants, experts, to obtain and verify critical qualitative commentary and opinion and quantitative statistics, to assess future market prospects.

The primary interviews and data collected as per the below protocols:
• By Designation: C-Level, D-Level, Others
• By Company Type: Tier 1, Tier 2, Tier 3

Secondary Data Sources such as Annual reports, Press releases, Analyst meetings, Conference calls, Investor presentations, Management statements, and SEC filings of IDO inhibitor players along with Regulatory Sites, Association, World bank, etc were used as sources secondary set of data.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, IDO inhibitor Study Sheds Light on
— The IDO inhibitor Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the IDO inhibitor industry Vendors. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where IDO inhibitor industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Vendors can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • BMS-986205
  • Dcellvax
  • Epacadostat
  • F-001287
  • Galanal
  • Others
By Application
  • Aolpecia
  • Cervical Cancer
  • Gastric Cancer
  • Glioma
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Cervical Cancer
      • 3.2.2. Growing Demand from Emerging Countries
    • 3.3. Market Challenges
      • 3.3.1. Increase in Purchasing Power of Developing Countries
    • 3.4. Market Trends
      • 3.4.1. Increasing Investment in Research & Development Globally
      • 3.4.2. Growing Gastric Cancer Worldwide
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global IDO inhibitor, by Type, Application and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global IDO inhibitor (Value)
      • 5.2.1. Global IDO inhibitor by: Type (Value)
        • 5.2.1.1. BMS-986205
        • 5.2.1.2. Dcellvax
        • 5.2.1.3. Epacadostat
        • 5.2.1.4. F-001287
        • 5.2.1.5. Galanal
        • 5.2.1.6. Others
      • 5.2.2. Global IDO inhibitor by: Application (Value)
        • 5.2.2.1. Aolpecia
        • 5.2.2.2. Cervical Cancer
        • 5.2.2.3. Gastric Cancer
        • 5.2.2.4. Glioma
        • 5.2.2.5. Others
      • 5.2.3. Global IDO inhibitor Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. IDO inhibitor: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bristol-Myers Squibb Company(United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer Inc (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Ensemble Therapeutics Corp (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Genentech Inc (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Globavir Biosciences Inc (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Incyte Corp (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. IO Biotech ApS (Denmark)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Kyowa Hakko Kirin (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Netherlands Translational Research Center BV (Netherlands)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global IDO inhibitor Sale, by Type, Application and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global IDO inhibitor (Value)
      • 7.2.1. Global IDO inhibitor by: Type (Value)
        • 7.2.1.1. BMS-986205
        • 7.2.1.2. Dcellvax
        • 7.2.1.3. Epacadostat
        • 7.2.1.4. F-001287
        • 7.2.1.5. Galanal
        • 7.2.1.6. Others
      • 7.2.2. Global IDO inhibitor by: Application (Value)
        • 7.2.2.1. Aolpecia
        • 7.2.2.2. Cervical Cancer
        • 7.2.2.3. Gastric Cancer
        • 7.2.2.4. Glioma
        • 7.2.2.5. Others
      • 7.2.3. Global IDO inhibitor Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. IDO inhibitor: by Type(USD Million)
  • Table 2. IDO inhibitor BMS-986205 , by Region USD Million (2018-2023)
  • Table 3. IDO inhibitor Dcellvax , by Region USD Million (2018-2023)
  • Table 4. IDO inhibitor Epacadostat , by Region USD Million (2018-2023)
  • Table 5. IDO inhibitor F-001287 , by Region USD Million (2018-2023)
  • Table 6. IDO inhibitor Galanal , by Region USD Million (2018-2023)
  • Table 7. IDO inhibitor Others , by Region USD Million (2018-2023)
  • Table 8. IDO inhibitor: by Application(USD Million)
  • Table 9. IDO inhibitor Aolpecia , by Region USD Million (2018-2023)
  • Table 10. IDO inhibitor Cervical Cancer , by Region USD Million (2018-2023)
  • Table 11. IDO inhibitor Gastric Cancer , by Region USD Million (2018-2023)
  • Table 12. IDO inhibitor Glioma , by Region USD Million (2018-2023)
  • Table 13. IDO inhibitor Others , by Region USD Million (2018-2023)
  • Table 14. South America IDO inhibitor, by Country USD Million (2018-2023)
  • Table 15. South America IDO inhibitor, by Type USD Million (2018-2023)
  • Table 16. South America IDO inhibitor, by Application USD Million (2018-2023)
  • Table 17. Brazil IDO inhibitor, by Type USD Million (2018-2023)
  • Table 18. Brazil IDO inhibitor, by Application USD Million (2018-2023)
  • Table 19. Argentina IDO inhibitor, by Type USD Million (2018-2023)
  • Table 20. Argentina IDO inhibitor, by Application USD Million (2018-2023)
  • Table 21. Rest of South America IDO inhibitor, by Type USD Million (2018-2023)
  • Table 22. Rest of South America IDO inhibitor, by Application USD Million (2018-2023)
  • Table 23. Asia Pacific IDO inhibitor, by Country USD Million (2018-2023)
  • Table 24. Asia Pacific IDO inhibitor, by Type USD Million (2018-2023)
  • Table 25. Asia Pacific IDO inhibitor, by Application USD Million (2018-2023)
  • Table 26. China IDO inhibitor, by Type USD Million (2018-2023)
  • Table 27. China IDO inhibitor, by Application USD Million (2018-2023)
  • Table 28. Japan IDO inhibitor, by Type USD Million (2018-2023)
  • Table 29. Japan IDO inhibitor, by Application USD Million (2018-2023)
  • Table 30. India IDO inhibitor, by Type USD Million (2018-2023)
  • Table 31. India IDO inhibitor, by Application USD Million (2018-2023)
  • Table 32. South Korea IDO inhibitor, by Type USD Million (2018-2023)
  • Table 33. South Korea IDO inhibitor, by Application USD Million (2018-2023)
  • Table 34. Taiwan IDO inhibitor, by Type USD Million (2018-2023)
  • Table 35. Taiwan IDO inhibitor, by Application USD Million (2018-2023)
  • Table 36. Australia IDO inhibitor, by Type USD Million (2018-2023)
  • Table 37. Australia IDO inhibitor, by Application USD Million (2018-2023)
  • Table 38. Rest of Asia-Pacific IDO inhibitor, by Type USD Million (2018-2023)
  • Table 39. Rest of Asia-Pacific IDO inhibitor, by Application USD Million (2018-2023)
  • Table 40. Europe IDO inhibitor, by Country USD Million (2018-2023)
  • Table 41. Europe IDO inhibitor, by Type USD Million (2018-2023)
  • Table 42. Europe IDO inhibitor, by Application USD Million (2018-2023)
  • Table 43. Germany IDO inhibitor, by Type USD Million (2018-2023)
  • Table 44. Germany IDO inhibitor, by Application USD Million (2018-2023)
  • Table 45. France IDO inhibitor, by Type USD Million (2018-2023)
  • Table 46. France IDO inhibitor, by Application USD Million (2018-2023)
  • Table 47. Italy IDO inhibitor, by Type USD Million (2018-2023)
  • Table 48. Italy IDO inhibitor, by Application USD Million (2018-2023)
  • Table 49. United Kingdom IDO inhibitor, by Type USD Million (2018-2023)
  • Table 50. United Kingdom IDO inhibitor, by Application USD Million (2018-2023)
  • Table 51. Netherlands IDO inhibitor, by Type USD Million (2018-2023)
  • Table 52. Netherlands IDO inhibitor, by Application USD Million (2018-2023)
  • Table 53. Rest of Europe IDO inhibitor, by Type USD Million (2018-2023)
  • Table 54. Rest of Europe IDO inhibitor, by Application USD Million (2018-2023)
  • Table 55. MEA IDO inhibitor, by Country USD Million (2018-2023)
  • Table 56. MEA IDO inhibitor, by Type USD Million (2018-2023)
  • Table 57. MEA IDO inhibitor, by Application USD Million (2018-2023)
  • Table 58. Middle East IDO inhibitor, by Type USD Million (2018-2023)
  • Table 59. Middle East IDO inhibitor, by Application USD Million (2018-2023)
  • Table 60. Africa IDO inhibitor, by Type USD Million (2018-2023)
  • Table 61. Africa IDO inhibitor, by Application USD Million (2018-2023)
  • Table 62. North America IDO inhibitor, by Country USD Million (2018-2023)
  • Table 63. North America IDO inhibitor, by Type USD Million (2018-2023)
  • Table 64. North America IDO inhibitor, by Application USD Million (2018-2023)
  • Table 65. United States IDO inhibitor, by Type USD Million (2018-2023)
  • Table 66. United States IDO inhibitor, by Application USD Million (2018-2023)
  • Table 67. Canada IDO inhibitor, by Type USD Million (2018-2023)
  • Table 68. Canada IDO inhibitor, by Application USD Million (2018-2023)
  • Table 69. Mexico IDO inhibitor, by Type USD Million (2018-2023)
  • Table 70. Mexico IDO inhibitor, by Application USD Million (2018-2023)
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Company Basic Information, Sales Area and Its Competitors
  • Table 80. Company Basic Information, Sales Area and Its Competitors
  • Table 81. IDO inhibitor: by Type(USD Million)
  • Table 82. IDO inhibitor BMS-986205 , by Region USD Million (2025-2030)
  • Table 83. IDO inhibitor Dcellvax , by Region USD Million (2025-2030)
  • Table 84. IDO inhibitor Epacadostat , by Region USD Million (2025-2030)
  • Table 85. IDO inhibitor F-001287 , by Region USD Million (2025-2030)
  • Table 86. IDO inhibitor Galanal , by Region USD Million (2025-2030)
  • Table 87. IDO inhibitor Others , by Region USD Million (2025-2030)
  • Table 88. IDO inhibitor: by Application(USD Million)
  • Table 89. IDO inhibitor Aolpecia , by Region USD Million (2025-2030)
  • Table 90. IDO inhibitor Cervical Cancer , by Region USD Million (2025-2030)
  • Table 91. IDO inhibitor Gastric Cancer , by Region USD Million (2025-2030)
  • Table 92. IDO inhibitor Glioma , by Region USD Million (2025-2030)
  • Table 93. IDO inhibitor Others , by Region USD Million (2025-2030)
  • Table 94. South America IDO inhibitor, by Country USD Million (2025-2030)
  • Table 95. South America IDO inhibitor, by Type USD Million (2025-2030)
  • Table 96. South America IDO inhibitor, by Application USD Million (2025-2030)
  • Table 97. Brazil IDO inhibitor, by Type USD Million (2025-2030)
  • Table 98. Brazil IDO inhibitor, by Application USD Million (2025-2030)
  • Table 99. Argentina IDO inhibitor, by Type USD Million (2025-2030)
  • Table 100. Argentina IDO inhibitor, by Application USD Million (2025-2030)
  • Table 101. Rest of South America IDO inhibitor, by Type USD Million (2025-2030)
  • Table 102. Rest of South America IDO inhibitor, by Application USD Million (2025-2030)
  • Table 103. Asia Pacific IDO inhibitor, by Country USD Million (2025-2030)
  • Table 104. Asia Pacific IDO inhibitor, by Type USD Million (2025-2030)
  • Table 105. Asia Pacific IDO inhibitor, by Application USD Million (2025-2030)
  • Table 106. China IDO inhibitor, by Type USD Million (2025-2030)
  • Table 107. China IDO inhibitor, by Application USD Million (2025-2030)
  • Table 108. Japan IDO inhibitor, by Type USD Million (2025-2030)
  • Table 109. Japan IDO inhibitor, by Application USD Million (2025-2030)
  • Table 110. India IDO inhibitor, by Type USD Million (2025-2030)
  • Table 111. India IDO inhibitor, by Application USD Million (2025-2030)
  • Table 112. South Korea IDO inhibitor, by Type USD Million (2025-2030)
  • Table 113. South Korea IDO inhibitor, by Application USD Million (2025-2030)
  • Table 114. Taiwan IDO inhibitor, by Type USD Million (2025-2030)
  • Table 115. Taiwan IDO inhibitor, by Application USD Million (2025-2030)
  • Table 116. Australia IDO inhibitor, by Type USD Million (2025-2030)
  • Table 117. Australia IDO inhibitor, by Application USD Million (2025-2030)
  • Table 118. Rest of Asia-Pacific IDO inhibitor, by Type USD Million (2025-2030)
  • Table 119. Rest of Asia-Pacific IDO inhibitor, by Application USD Million (2025-2030)
  • Table 120. Europe IDO inhibitor, by Country USD Million (2025-2030)
  • Table 121. Europe IDO inhibitor, by Type USD Million (2025-2030)
  • Table 122. Europe IDO inhibitor, by Application USD Million (2025-2030)
  • Table 123. Germany IDO inhibitor, by Type USD Million (2025-2030)
  • Table 124. Germany IDO inhibitor, by Application USD Million (2025-2030)
  • Table 125. France IDO inhibitor, by Type USD Million (2025-2030)
  • Table 126. France IDO inhibitor, by Application USD Million (2025-2030)
  • Table 127. Italy IDO inhibitor, by Type USD Million (2025-2030)
  • Table 128. Italy IDO inhibitor, by Application USD Million (2025-2030)
  • Table 129. United Kingdom IDO inhibitor, by Type USD Million (2025-2030)
  • Table 130. United Kingdom IDO inhibitor, by Application USD Million (2025-2030)
  • Table 131. Netherlands IDO inhibitor, by Type USD Million (2025-2030)
  • Table 132. Netherlands IDO inhibitor, by Application USD Million (2025-2030)
  • Table 133. Rest of Europe IDO inhibitor, by Type USD Million (2025-2030)
  • Table 134. Rest of Europe IDO inhibitor, by Application USD Million (2025-2030)
  • Table 135. MEA IDO inhibitor, by Country USD Million (2025-2030)
  • Table 136. MEA IDO inhibitor, by Type USD Million (2025-2030)
  • Table 137. MEA IDO inhibitor, by Application USD Million (2025-2030)
  • Table 138. Middle East IDO inhibitor, by Type USD Million (2025-2030)
  • Table 139. Middle East IDO inhibitor, by Application USD Million (2025-2030)
  • Table 140. Africa IDO inhibitor, by Type USD Million (2025-2030)
  • Table 141. Africa IDO inhibitor, by Application USD Million (2025-2030)
  • Table 142. North America IDO inhibitor, by Country USD Million (2025-2030)
  • Table 143. North America IDO inhibitor, by Type USD Million (2025-2030)
  • Table 144. North America IDO inhibitor, by Application USD Million (2025-2030)
  • Table 145. United States IDO inhibitor, by Type USD Million (2025-2030)
  • Table 146. United States IDO inhibitor, by Application USD Million (2025-2030)
  • Table 147. Canada IDO inhibitor, by Type USD Million (2025-2030)
  • Table 148. Canada IDO inhibitor, by Application USD Million (2025-2030)
  • Table 149. Mexico IDO inhibitor, by Type USD Million (2025-2030)
  • Table 150. Mexico IDO inhibitor, by Application USD Million (2025-2030)
  • Table 151. Research Programs/Design for This Report
  • Table 152. Key Data Information from Secondary Sources
  • Table 153. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global IDO inhibitor: by Type USD Million (2018-2023)
  • Figure 5. Global IDO inhibitor: by Application USD Million (2018-2023)
  • Figure 6. South America IDO inhibitor Share (%), by Country
  • Figure 7. Asia Pacific IDO inhibitor Share (%), by Country
  • Figure 8. Europe IDO inhibitor Share (%), by Country
  • Figure 9. MEA IDO inhibitor Share (%), by Country
  • Figure 10. North America IDO inhibitor Share (%), by Country
  • Figure 11. Global IDO inhibitor share by Players 2023 (%)
  • Figure 12. Global IDO inhibitor share by Players (Top 3) 2023(%)
  • Figure 13. Global IDO inhibitor share by Players (Top 5) 2023(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Bristol-Myers Squibb Company(United States) Revenue, Net Income and Gross profit
  • Figure 16. Bristol-Myers Squibb Company(United States) Revenue: by Geography 2023
  • Figure 17. Pfizer Inc (United States) Revenue, Net Income and Gross profit
  • Figure 18. Pfizer Inc (United States) Revenue: by Geography 2023
  • Figure 19. Ensemble Therapeutics Corp (United States) Revenue, Net Income and Gross profit
  • Figure 20. Ensemble Therapeutics Corp (United States) Revenue: by Geography 2023
  • Figure 21. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2023
  • Figure 23. Genentech Inc (United States) Revenue, Net Income and Gross profit
  • Figure 24. Genentech Inc (United States) Revenue: by Geography 2023
  • Figure 25. Globavir Biosciences Inc (United States) Revenue, Net Income and Gross profit
  • Figure 26. Globavir Biosciences Inc (United States) Revenue: by Geography 2023
  • Figure 27. Incyte Corp (United States) Revenue, Net Income and Gross profit
  • Figure 28. Incyte Corp (United States) Revenue: by Geography 2023
  • Figure 29. IO Biotech ApS (Denmark) Revenue, Net Income and Gross profit
  • Figure 30. IO Biotech ApS (Denmark) Revenue: by Geography 2023
  • Figure 31. Kyowa Hakko Kirin (Japan) Revenue, Net Income and Gross profit
  • Figure 32. Kyowa Hakko Kirin (Japan) Revenue: by Geography 2023
  • Figure 33. Netherlands Translational Research Center BV (Netherlands) Revenue, Net Income and Gross profit
  • Figure 34. Netherlands Translational Research Center BV (Netherlands) Revenue: by Geography 2023
  • Figure 35. Global IDO inhibitor: by Type USD Million (2025-2030)
  • Figure 36. Global IDO inhibitor: by Application USD Million (2025-2030)
  • Figure 37. South America IDO inhibitor Share (%), by Country
  • Figure 38. Asia Pacific IDO inhibitor Share (%), by Country
  • Figure 39. Europe IDO inhibitor Share (%), by Country
  • Figure 40. MEA IDO inhibitor Share (%), by Country
  • Figure 41. North America IDO inhibitor Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Bristol-Myers Squibb Company(United States)
  • Pfizer Inc (United States)
  • Ensemble Therapeutics Corp (United States)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Genentech Inc (United States)
  • Globavir Biosciences Inc (United States)
  • Incyte Corp (United States)
  • IO Biotech ApS (Denmark)
  • Kyowa Hakko Kirin (Japan)
  • Netherlands Translational Research Center BV (Netherlands)
Additional players considered in the study are as follows:
BirchBioMed Inc (United States) , NewLink Genetics Corp (United States) , Redx Pharma Plc (United Kingdom) , Regen BioPharma Inc (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 226 Pages 82 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global IDO inhibitor Quantitative research analysis
Global IDO inhibitor Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2018-2023; Base year: 2023; Forecast period: 2024 to 2030
Companies that are profiled in Global IDO inhibitor Market are Bristol-Myers Squibb Company(United States), Pfizer Inc (United States), Ensemble Therapeutics Corp (United States), F. Hoffmann-La Roche Ltd (Switzerland), Genentech Inc (United States), Globavir Biosciences Inc (United States), Incyte Corp (United States), IO Biotech ApS (Denmark), Kyowa Hakko Kirin (Japan) and Netherlands Translational Research Center BV (Netherlands) etc.
Aolpecia segment in Global market to hold robust market share owing to "Rising Prevalence of Cervical Cancer ".
AMA Research predicts that United States Vendors will contribute to the maximum growth of Global IDO inhibitor market throughout the forecasted period.

Know More About Global IDO inhibitor Report?

Have a Query? Click Here

Other Related Reports

Copper Paste Comprehensive Study by Type (Lubricant Paste, Conductive Paste), Application (Printed Electronics, Industrial Machinery, Power Electronics, Brake Noise Absorbent, Others), Distribution C...
$ 3650
Metal Polish Comprehensive Study by Type (Paste, Liquid, Others), Application (Guns, Knives, Others), End User (Industrial, Automotive, Metal Manufacturing, Household Uses) Players and Region - Globa...
$ 3500
Short Oil Alkyd Resins Comprehensive Study by Application (Industrial Baking Enamels, Metal Primers, Traffic Paint, Clear Wood Finishes, Industrial Wood Primers, Others), Packaging Type (Barrel, Iron...
$ 3750
Fireproof Insulation Comprehensive Study by Application (Residential Buildings, Commercial Buildings), Distribution Channel (Offline, Online), Material (Glass Wool, Stone Wool, Plastic Foam, Others) ...
$ 3500
Vinyl Sulfone Comprehensive Study by Type (Di-Vinyl Sulfone, Phenyl Vinyl Sulfone, Methyl Vinyl Sulfone, Vinyl Sulfone Ester, Others), Application (Dyestuff Manufacturing, Intermediate in Chemical In...
$ 3450
Home Care Chemicals Comprehensive Study by Type (Surfactants, Solvents, Additives, Pigment, Others), Application (Dishwashing, Hard Surface Cleaning, Laundry/Fabric Care, Others), Distribution Channe...
$ 3800